AC
ENGNW icon

Aristeia Capital’s enGene Therapeutics Warrants ENGNW Stock Holding History

Aristeia Capital’s Portfolio ENGNW Stock Details ENGNW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$47.7K Buy
197,678
+33,167
+20% +$34.5K ﹤0.01% 678
2026
Q1 		$445K Buy
+164,511
New +$487K 0.01% 395
2024
Q1 		– Sell
-24,045
Closed -$28.3K – 300
2023
Q4 		$28.3K Buy
+24,045
New +$18.5K ﹤0.01% 128

Other funds holding ENGNW

FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $21.5B AUM 81.81% 1-Year Est. Return
LP
LMR Partners London, United Kingdom $26.8B AUM 68.38% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
SG
StoneX Group New York $2.48B AUM 33.54% 1-Year Est. Return
CL
CSS LLC Chicago, Illinois $2.57B AUM 67.1% 1-Year Est. Return
CS
Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return

Aristeia Capital's ENGNW Position: Q2 2026 in Review

Aristeia Capital increased its enGene Therapeutics Warrants (ENGNW) stake by 20% in Q2 2026, buying an estimated $34.5K and bringing the position to 197,678 shares worth $47.7K. The position accounts for ﹤0.01% of the portfolio, ranked #678.

Aristeia Capital first reported a position in ENGNW in Q4 2023 and has held it in 3 quarters since. The position peaked at $445K in Q1 2026. 11 funds tracked by Wall St. Rank hold ENGNW as of Q2 2026.

  • Aristeia Capital held 197,678 shares of enGene Therapeutics Warrants worth $47.7K as of Q2 2026.
  • Aristeia Capital bought 33,167 enGene Therapeutics Warrants shares in Q2 2026, an estimated $34.5K.
  • enGene Therapeutics Warrants made up ﹤0.01% of Aristeia Capital's portfolio in Q2 2026, its #678 holding.
  • Aristeia Capital first reported a position in enGene Therapeutics Warrants in Q4 2023 and has held it in 3 quarters since.
  • Aristeia Capital's enGene Therapeutics Warrants position peaked at $445K in Q1 2026.
  • 11 funds tracked by Wall St. Rank held enGene Therapeutics Warrants as of Q2 2026.

Based on Aristeia Capital's 13F filing for Q2 2026, filed 14 Aug 2026.